Multidrug therapy is used to prevent the emergence of drug resistant mutants during the long (6- to 9-month) duration of treatment. (Organisms that become resistant to one drug will be inhibited by the other.) Isoniazid (INH), a bactericidal drug, is the mainstay of treatment. Treatment for most patients with drug-susceptible pulmonary tuberculosis is with four drugs (rifampin, isoniazid, pyrazinamide, and ethambutol; often abbreviated RIPE) for 2 months and two drugs (isoniazid and rifampin) for 4 months. In patients who are immunocompromised (e.g., AIDS patients), who have disseminated disease, or who are likely to have INH-resistant organisms, a fourth drug, ethambutol, is added, and all four drugs are given for 9 to 12 months. A shorter, 4-month course of a combination of moxifloxacin and rifapentine is also useful in the treatment of tuberculosis caused by drug-susceptible strains.
Although therapy is usually given for months, the patient’s sputum becomes noninfectious within 2 to 3 weeks. The necessity for protracted therapy is attributed to (1) the intracellular location of the organism; (2) caseous material, which blocks penetration by the drug; (3) the slow growth of the organism; and (4) metabolically inactive “persisters” within the lesion. Because metabolically inactive organisms may not be killed by antitubercular drugs, treatment may not eradicate the infection, and reactivation of the disease may occur in the future.
Lymphadenitis, including cervical lymphadenitis (scrofula) caused by M. tuberculosis, should be treated with the drug regimens described earlier for disseminated disease. Scrofula caused by M. scrofulaceum can be treated by surgical excision of the single cervical lymph node, but alternative approaches exist. A complete discussion of these is beyond the scope of this book.
Treatment of latent (asymptomatic) infections consists of rifampin for 4 months or INH plus rifapentine for 3 months. A course of INH taken for 6 to 9 months is also effective. This approach is most often used in asymptomatic patients whose PPD skin test or IGRA test recently converted to positive. The risk of symptomatic infection is greatest within the first 2 years after infection, so INH is particularly indicated for these “recent converters.” INH is also used in children exposed to patients with symptomatic tuberculosis. Patients who receive INH should be evaluated for drug-induced hepatitis, especially those over the age of 35 years. Rifampin can be used in those exposed to INH resistant strains. A combination of rifampin and pyrazinamide should not be used because it can cause severe liver injury.
Resistance to INH and other antituberculosis drugs is being seen with increasing frequency in the United States, especially in immigrants from Southeast Asia and Latin America. Strains of M. tuberculosis resistant to multiple drugs (MDR strains) have emerged, primarily in AIDS patients. The most common pattern is resistance to both INH and rifampin, but some iso lates are resistant to three or more drugs. The treatment of MDR organisms usually involves the use of five drugs (Table1). The precise recommendations depend on the resistance pattern of the isolate and are beyond the scope of this book.

Table1. Choice of Five Drugs for Treatment of MDR-Tuberculosis
Previous treatment for tuberculosis predisposes to the selection of these MDR organisms. Noncompliance (i.e., the failure of patients to complete the full course of therapy) is a major fac tor in allowing the resistant organisms to survive. One approach to the problem of noncompliance is directly observed therapy (DOT), in which healthcare workers observe the patient taking the medication.
The strains of M. tuberculosis resistant to INH, rifampin, a fluoroquinolone, and at least one additional drug are called extensively drug-resistant (XDR) strains. XDR strains emerged in 2005 among HIV-infected patients in South Africa.
Note that M. tuberculosis produces β-lactamase, rendering the organism resistant to many penicillins and cephalosporins. Trials using amoxicillin-clavulanate to treat active tuberculosis were unsuccessful.